Conservative drug therapy and walking exercise in stage IIb peripheral arterial occlusion disease
- PMID: 2431197
- DOI: 10.1007/BF01757212
Conservative drug therapy and walking exercise in stage IIb peripheral arterial occlusion disease
Abstract
In cases of peripheral arterial occlusion disease in Fontaine's stage IIb (PAOD IIb) with a walking distance of less than 200 m, the therapy that has priority, besides removing risk factors, is physical exercise. Very often it seems that concomitant rheological treatment with drugs is advisable to support the therapy and to improve compliance. The experience gained in the last 30 months in the treatment of PAOD IIb in a large angiological outpatient establishment is presented. All the patients were given thorough medical examination before the start of the therapy, and their angiological and rheological status was recorded. Depending on the results of the examinations, the patients with PAOD IIb were given one of three treatment variants: Patients with a haematocrit less than 43% and moderately altered rheology (group I; therapy: physical exercise). Patients with a haematocrit less than 43% and severely altered rheology, in particular increased erythrocyte rigidity (group II; therapy: physical exercise combined with naftidrofuryl treatment). Patients with a haematocrit of 43% or more and severely altered rheology (group III; therapy: physical exercise with haemodilution combined with naftidrofuryl treatment). Before the drug treatment was started, the possibility of surgical reconstruction of the vessels or angioplasty was discussed and the conservative therapy was undertaken only after surgery or when surgery had been rejected. Every course of treatment included reducing the risk factors as far as possible. All three conservative therapies were implemented for a period of at least 6 months. The increase in the walking distance was 157% (n = 27) after physical exercise alone, 238% (n = 27) with the naftidrofuryl combination therapy and 311% (n = 27) with the naftidrofuryl/haemodilution combination therapy.
Similar articles
-
Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.Drugs Aging. 1996 Apr;8(4):299-322. doi: 10.2165/00002512-199608040-00005. Drugs Aging. 1996. PMID: 8920176 Review.
-
[Hemorheologic therapy in peripheral arterial occlusive disease].Fortschr Med. 1984 Oct 4;102(37):921-4. Fortschr Med. 1984. PMID: 6500451 German.
-
Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb.J Intern Med. 1990 Feb;227(2):107-14. doi: 10.1111/j.1365-2796.1990.tb00127.x. J Intern Med. 1990. PMID: 1688914 Clinical Trial.
-
[Conservative treatment of arterial occlusive diseases with naftidrofuryl hydrogen oxalate (author's transl)].MMW Munch Med Wochenschr. 1976 Sep 3;118(36):1131-4. MMW Munch Med Wochenschr. 1976. PMID: 823407 German.
-
[Naftidrofuryl in arterial obstructive disease: A systematic revue of the literature].Rev Med Interne. 2020 Feb;41(2):89-97. doi: 10.1016/j.revmed.2019.10.001. Epub 2019 Oct 25. Rev Med Interne. 2020. PMID: 31669163 French.
Cited by
-
Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.Drugs Aging. 1996 Apr;8(4):299-322. doi: 10.2165/00002512-199608040-00005. Drugs Aging. 1996. PMID: 8920176 Review.